Group 1: Financial Performance - The gross profit margin for cataract business increased due to the promotion of multi-functional intraocular lenses and upgrades to high-end refractive cataract surgeries, leading to a rise in average transaction value [2] - The revenue share of comprehensive eye disease treatments is relatively low, with significant variations in gross profit margins across different treatment types [3] Group 2: Impact of COVID-19 - Hospitals severely affected by the pandemic in Q2 include Shanghai, Changchun, and Beijing, with seasonal characteristics observed in refractive and optical businesses [3][5] - The pandemic has led to a decrease in revenue for high-margin projects like nystagmus and lacrimal duct surgeries due to restricted cross-regional operations [3] Group 3: Expansion Plans - The company currently operates 23 hospitals and plans to open additional locations in the second half of the year and early next year, following a "national chain + local integration" strategy [3] - The company is focusing on the South China region for future expansion, considering acquisitions to enhance market presence [4] Group 4: Business Strategy - The company aims to increase the proportion of optical business revenue, having established an independent optical division and introduced advanced myopia control products [4] - The current focus remains on expanding specialized eye hospitals while promoting optical services through these facilities [4] Group 5: Market Positioning - The majority of patients come from provincial capital cities, with a low proportion from other regions; the company plans to maintain focus on first- and second-tier cities for the next three to five years [5] - The strategy emphasizes deepening existing market penetration to solidify brand recognition and patient loyalty, thereby reducing investment risks [5]

证券代码：301239 证券简称：普瑞眼科 成都普瑞眼科医院股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | |----------------|--------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | 投资者关系活动 | 特定对象调研 | □分析师会议 | | 类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 | □路演活动 | | | □现场参观 | | | | □其他 | （请文字说明其他活动内容） | | 参与单位名称及 | | 中信建投：吴严；海通证券：余文心；海通证券：梁广楷、陈 | | 人员姓名 | | 铭；东北证券：刘宇腾、叶菁、古翰羲；华西证券：崔文亮、 程仲瑶；太平洋证券：盛丽华、 ...

Financial Performance - The company's operating revenue for Q3 2022 was CNY 543,069,898.63, representing a 6.31% increase year-over-year[6]. - The net profit attributable to shareholders for the same period was CNY 42,739,887.75, a decrease of 19.35% compared to the previous year[6]. - The basic earnings per share decreased by 38.30% to CNY 0.29[6]. - Total operating revenue for the period reached ¥1,432,759,189.01, an increase of approximately 5.5% compared to ¥1,357,493,892.62 in the previous period[30]. - Net profit for the period was ¥94,004,084.92, a decrease of approximately 20.5% from ¥118,332,998.14 in the previous period[34]. - The total comprehensive income attributable to the parent company was 94,004,084.92, down from 118,332,735.47 in the previous period[36]. - Basic and diluted earnings per share were both 0.75, compared to 1.05 in the previous period[36]. Assets and Liabilities - Total assets increased by 64.23% to CNY 3,819,466,956.20 compared to the end of the previous year[6]. - The company's total assets increased to ¥3,819,466,956.20, compared to ¥2,325,623,991.84, marking a growth of about 64.3%[29]. - Total liabilities rose to ¥1,678,688,110.30, up from ¥1,377,322,609.70, indicating an increase of approximately 21.8%[29]. - The equity attributable to shareholders of the parent company reached ¥2,140,778,845.90, compared to ¥948,301,382.14, representing a growth of about 126.5%[29]. - The company’s long-term liabilities totaled ¥1,012,057,592.73, up from ¥887,694,447.09, indicating an increase of approximately 14.1%[29]. Cash Flow - Cash flow from operating activities decreased by 6% to CNY 262,784,150.96 due to rising costs[14]. - Cash inflow from operating activities totaled 1,436,491,234.49, an increase from 1,380,931,817.60 in the previous period[37]. - Net cash flow from operating activities was 262,784,150.96, down from 280,012,786.07 in the previous period[40]. - Cash outflow from investing activities was 442,224,509.71, compared to 314,019,922.53 in the previous period[40]. - Net cash flow from financing activities was 1,137,926,181.07, significantly up from 10,500,271.36 in the previous period[40]. - The ending cash and cash equivalents balance was 1,148,370,772.11, compared to 261,806,637.04 in the previous period[40]. - The company reported a net increase in cash and cash equivalents of 977,596,242.79, compared to a decrease of 23,294,176.84 in the previous period[40]. Investments and R&D - R&D expenses increased by CNY 4,360,000, focusing on clinical applications and digital research related to ophthalmology[14]. - Research and development expenses for the period were ¥4,357,149.04, compared to ¥0.00 in the previous period, indicating a new investment in innovation[30]. - The company reported an increase in long-term equity investments to ¥238,570,978.87 from ¥168,881,986.56, reflecting a growth of approximately 41.2%[29]. - The company plans to invest RMB 10,380 million to establish a wholly-owned subsidiary for the new Shenzhen Puri Eye Hospital project[22]. - An additional investment of RMB 7,410.96 million is allocated for the construction of the Hubei Puri Eye Hospital project[22]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,694[14]. - The company completed the election of the third board of directors and the third supervisory board, with new members appointed on October 10, 2022[21]. - The company has not disclosed any related party transactions or concerted actions among shareholders[18]. - The total number of shareholders with priority shares and their holdings was not applicable for this report[19]. - The company has not reported any changes in restricted shares[19]. - The company’s actual controller holds 100% equity in Chengdu Puri Century Investment Co., Ltd.[18]. Current Assets - The company reported a total current asset of RMB 1,148,370,772.11, an increase from RMB 170,774,529.32 in the previous period[23]. - Accounts receivable amounted to RMB 87,054,798.85, up from RMB 54,302,935.42, indicating a growth of approximately 60.3%[23]. - The total current assets amounted to ¥1,524,094,858.92, compared to ¥419,499,744.51, showing a significant increase of about 263.5%[29]. Other Information - The company opened multiple new hospitals, contributing to a 6% increase in sales revenue despite challenges from COVID-19[11]. - Cash and cash equivalents increased significantly, reflecting a strong liquidity position[23]. - The company did not undergo an audit for the third quarter report[41].

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2022, representing a year-on-year increase of 20%[24]. - The number of patients treated in the first half of 2022 reached 150,000, an increase of 15% compared to the same period last year[24]. - The gross profit margin for the first half of 2022 was 60%, maintaining the same level as the previous year[24]. - The net profit for the first half of 2022 was RMB 80 million, up 25% year-on-year[24]. - The company's operating revenue for the first half of 2022 was approximately ¥889.69 million, representing a 5.08% increase compared to ¥846.65 million in the same period last year[32]. - The net profit attributable to shareholders decreased by 21.54% to ¥51.26 million from ¥65.34 million year-on-year[32]. - The net cash flow from operating activities of approximately ¥48.77 million, down 19.25% from ¥60.39 million in the previous year[32]. - The basic earnings per share decreased by 20.69% to ¥0.46 from ¥0.58 year-on-year[32]. - The company reported a net profit from its subsidiary Kunming Puri Eye Hospital reached approximately CNY 23.14 million, contributing significantly to overall performance[80]. - The company is facing short-term profit fluctuations due to rapid expansion, with new hospitals requiring a three to five-year cultivation period before reaching breakeven[84]. Market Expansion and Strategy - The company plans to expand its market presence by opening 10 new clinics in the next 12 months[24]. - The company is exploring potential acquisition opportunities to enhance its service offerings[24]. - The company has established 23 specialized eye hospitals and 3 outpatient departments across major cities, enhancing its national network presence[53]. - The company opened four new hospitals in Kunming, Hefei, Nanchang, and Guangzhou Panyu, laying a solid foundation for future business expansion[54]. - The company is focusing on high-end refractive cataract surgeries to meet the increasing demand for quality vision among middle-aged and elderly patients[58]. - The company aims to enhance its market presence and explore potential mergers and acquisitions as part of its growth strategy[165]. Research and Development - The company is investing RMB 50 million in research and development for new ophthalmic technologies[24]. - The company's R&D investment reached ¥2,547,946.77, a significant increase from ¥0.00 in the previous year, primarily for clinical applications and digital research related to ophthalmology[65]. - The introduction of advanced medical technologies, including the fifth-generation digital and intelligent orthokeratology lens fitting technology, aims to enhance personalized treatment options[59]. - The company has identified a significant growth potential in the ophthalmic sector, driven by increasing health awareness and aging population trends[43]. Financial Position and Assets - The total assets of the company as of June 30, 2022, amounted to RMB 1.2 billion, a 10% increase from the end of 2021[24]. - The total assets at the end of the reporting period reached ¥3.76 billion, a significant increase of 61.65% compared to ¥2.33 billion at the end of the previous year[32]. - The net assets attributable to shareholders increased by 121.24% to ¥2.10 billion from ¥948.30 million year-on-year[32]. - The company reported a total of 1,574,762,591.77 CNY in current assets, indicating a robust financial position[193]. - Cash and cash equivalents reached CNY 1.28 billion, up from CNY 170.77 million at the start of the year, indicating strong liquidity growth[193]. - The company's cash and cash equivalents accounted for 33.97% of total assets at the end of the reporting period, up from 7.34% at the end of the previous year, due to the influx of funds from the new share issuance[68]. Challenges and Risks - The ongoing COVID-19 pandemic has posed challenges to the company's operations, affecting the performance of several hospitals[86]. - The company is experiencing intensified competition in the ophthalmology sector, necessitating continuous improvement in brand, technology, and service quality to maintain competitiveness[87]. - The company is actively managing risks associated with medical accidents by implementing comprehensive medical management systems to ensure quality and safety[85]. Corporate Governance and Compliance - The company has not reported any significant environmental penalties during the reporting period, confirming compliance with environmental regulations[101]. - The company has not indicated any recent lease terminations, suggesting a stable operational environment[139]. - The company has not faced any bankruptcy restructuring matters during the reporting period[109]. - The company has not reported any major litigation or arbitration matters during the reporting period[110]. - The company has not engaged in any significant related party transactions during the reporting period[113]. Shareholder Information and IPO - The company completed its initial public offering (IPO) by issuing 37,404,762 shares at a price of RMB 33.65 per share, increasing total shares from 112,214,286 to 149,619,048[160]. - Major shareholder Chengdu Puri Century Investment holds 35.91% of the shares, totaling 53,729,585 shares[171]. - The company has a lock-up period for certain shareholders, with shares held by major shareholders set to be released on July 4, 2025[162]. - The total number of shares subject to lock-up is 114,143,208, with 1,928,922 shares released during the reporting period[166]. - The company plans to utilize the funds raised from the IPO for market expansion and new technology development[165].